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Background: Females show greater sensitivity than males to several modalities of experimental pain. However, the 
gender differences in paclitaxel-induced neuropathic pain have not been studied. The current study examined the 
gender differences in neuropathic pain behavior and the effect of analgesics in a paclitaxel-induced neuropathic pain 
model in rats. 
Methods: Neuropathic pain was induced by intraperitoneal injection of paclitaxel (2 mg/kg) on 4 alternate days in 
Sprague-Dawley rats of both genders. Mechanical allodynia was measured using a von Frey filament. The gender 
differences in analgesic responses were determined after administration of morphine (2 or 5 mg/kg), ketamine (2 or 
5 mg/kg), or combined morphine (2 mg/kg) and ketamine (2 mg/kg). 
Results: Paclitaxel induced mechanical allodynia, which began to manifest on day 4, peaked within 10 days, and 
plateaued for at least 2 months after the first paclitaxel injection. No gender difference in the manifestation of 
mechanical allodynia was observed. A 2 mg/kg dose of ketamine increased the mechanical threshold only in males. 
The 5 mg/kg dose of ketamine significantly increased the mechanical threshold in both genders. Morphine (2 and 
5 mg/kg) dose-dependently increased the mechanical thresholds in both genders. The 2 mg/kg dose of ketamine 
enhanced the antinociceptive effect of 2 mg/kg morphine only in females. 
Conclusions: No gender difference in paclitaxel-induced neuropathic pain or analgesic response to ketamine or 
morphine was observed in Sprague-Dawley rats. Low dose ketamine enhanced the analgesic effect of morphine on 
paclitaxel-induced mechanical allodynia but only in female rats. (Korean J Anesthesiol 2012; 62: 66-72)
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Introduction
Although cancer treatment with chemotherapeutic agents, 
such as taxanes, vinca alkaloids, and platinum complexes 
increases patient survival times, side effects may diminish quality 
of life. Paclitaxel (PAC) is a widely used chemotherapeutic drug 
for treating breast cancer, cervical cancer, ovarian cancer, non-
small cell lung carcinomas, and Kaposi’s sarcoma. PAC binds 
to β-tubulin of microtubules, stabilizing microtubules and 
enhancing microtubule polymerization [1]. PAC induces a dose-
limiting side effect, neuropathic pain, which is characterized by 
numbness, tingling, and burning. The mechanisms producing 
this neuropathic pain are not fully understood [2,3]. 
Many factors influence the incidence of chemotherapy-
induced peripheral neuropathy, including patient age, dose 
intensity, cumulative dose, therapy duration, co-administration 
of other chemotherapeutic agents, and pre-existing conditions. 
Fifty-five percent of patients receiving a cumulative dose of 200 
mg/m
2 PAC developed sensory disturbances compared to only 
30% receiving 175 mg/m
2 [3]. 
Investigating chemotherapy-induced neuropathic pain is 
particularly difficult, because neuropathic pain may arise from 
multiple causes (chemotherapy, tumor effects, radiotherapy, 
surgical trauma, etc.). Animal models present a simpler 
situation. PAC-induced neuropathic pain (PINP) in rats is a 
commonly used model of chemotherapy-induced neuropathic 
pain. PAC-treated rats have pronounced mechanical allodynia, 
cold allodynia, and mechanical hyperalgesia but little or no heat 
hyperalgesia [2]. Nerve trauma models produce pronounced 
heat hyperalgesia. The observation that drug-induced 
neuropathic pain is related to an abnormality in mitochondria 
within sensory axons has been reported [4]. Flatters and Bennett 
[5] suggested that PAC induces degeneration or dysfunction of 
axonal microtubules without axonal degeneration or disruption 
of the axonal cytoskeleton. Massive axonal degeneration occurs 
in the nerve trauma model [6]
PAC is frequently used in female patients, but most animal 
experiments of PINP have been conducted with male rats or 
mice. Gender is a critical factor modulating the experience 
of pain. Males and females experience pain differently 
and respond differentially to specific classes of analgesic 
medications. A quantitative review of the literature regarding 
gender differences of experimental pain responses concluded 
that females show greater sensitivity to several modalities of 
experimental pain than males [7]. However, the relationship 
between pain behavior and gender differences in PINP has 
not been studied, and the gender differences in the clinical 
incidence of neuropathic pain after PAC administration have 
not been reported. 
The objective of this study was to investigate the gender 
difference in pain behavior after a PAC injection in rats and to 
compare the effect of analgesics in this pain model. 
Materials and Methods 
Materials 
Sprague-Dawley rats (n = 24), weighing 150 to 250 g at the 
start of the experiments, were used. Two rats per cage were 
housed under standard laboratory conditions with controlled 
room temperature (23
oC) and a 12-hour light/dark cycle. This 
experimental protocol was approved by the Institutional Animal 
Care and Use Committee. 
Animals were divided into two groups of males (n = 12) and 
females (n = 12). Each group was subdivided into a saline group 
(n = 4 each) and a PAC group (n = 8 each). Body weight was 
recorded on each experimental day. 
Injection of PAC and development of neuropathic pain 
Rats were placed in a Plexiglas box and anesthetized with 
4% isoflurane and oxygen. After induction of anesthesia, rats 
were randomly injected intraperitoneally with 1 ml/kg saline 
or 1 ml/kg PAC (Taxol; Bristol-Myers-Squibb, New York, NY, 
USA, 2 mg/ml). PAC was diluted with saline to create a 2 mg/ml 
concentration that was injected intraperitoneally (2 mg/kg) on 
4 alternate days (days 1, 3, 5, and 7). Body weight was recorded 
before the PAC or saline injections. 
Behavioral testing 
The behavioral test was conducted by an examiner who 
was blinded to the groups. The measured test was the foot 
withdrawal threshold in response to mechanical stimuli applied 
to the hind paws. Rats were placed in a Plexiglas chamber 
with a mesh floor. Before testing, rats were habituated to 
the testing environment for more than 15 minutes. Baseline 
measurements were taken prior to PAC administration. The 
plantar surface of the hind paw (sciatic nerve territory) was 
tested with a calibrated von Frey filament (3.65, 3.87, 4.10, 4.31, 
4.52, 4.74, 4.92, and 5.16). The von Frey filament was applied 
perpendicularly to the most sensitive areas of the plantar 
surface at the center area of the paw or the base of the third or 
fourth toes with sufficient force to bend the filament slightly for 
2-3 seconds. Abrupt withdrawal of the foot during stimulation 
or immediately after stimulus removal was considered a posi-
tive response. 
The up-down method of Dixon [8] was used for testing the 
withdrawal threshold. The first stimulus was always the 4.31 
filament. When there was a positive response, the next lower 68 www.ekja.org
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filament was used, and when no response was observed, the 
next higher filament was applied. This testing pattern continued 
until responses to the sixth von Frey stimuli from the first 
change in response were measured. The responses were then 
converted into a 50% threshold value using the formula: 50% 
threshold = 10
(X + kd)/10
4, where X is the value of the final von Frey 
hair in log units, k is the tabular value for the pattern of positive 
or negative responses, and d is the mean difference between 
stimuli in log units (0.22). When negative or positive responses 
were still observed for the 3.84 or 5.18 filament, values of 0.3 or 
15.0 g were assigned, respectively, by assuming a value of ± 0.5 
for k. Testing was conducted on the day PAC was injected, and 
2, 5, 7, 9, 11, 14, 18, 20, 22, 24, and 28 days after the fourth PAC 
injection. 
Responses to analgesic drugs 
The responses to analgesics were determined after intraperi-
toneal (i.p.) administration of 2 mg/kg ketamine, 5 mg/kg 
ketamine, 2 mg/kg morphine, 5 mg/kg morphine, and 2 mg/
kg morphine plus 2 mg/kg ketamine at 32-60 days after PAC 
injection. Drugs were diluted with saline, and the concentration 
was adjusted to make an equal volume of 1 ml/kg. Mechanical 
thresholds of the right hind paws were measured before and 
20 minutes after intraperitoneal injection of each drug. A 7-day 
treatment interval was used to avoid overlap. The pre-injection 
withdrawal threshold was checked to confirm the absence of 
the previous treatment. 
Statistical analysis 
Data are presented as mean ± standard deviation. The Statview 
5.0 program (SAS Institute Inc., Cary, NC, USA) was used to 
test statistical significance. The withdrawal thresholds of each 
group were compared with a repeated- measures analysis of 
variance followed by Scheffe's post hoc test. The demographic 
data and responses to the analgesic drugs were compared with 
the Mann-Whitney U and Wilcoxon signed-rank tests. A P < 0.05 
was considered statistically significant. 
Results 
Rats showed normal gains in body weight during PAC or 
saline treatment. No significant difference in body weight 
was observed between the saline and PAC groups (Fig. 1). No 
significant difference was observed between the mechanical 
thresholds of the right and left hind paws. Data were calculated 
using the mean value obtained from both hind paws. The 
mechanical threshold decreased at PAC injection day 3 (P < 0.05) 
and was maintained to day 28 after the fourth PAC injection in 
the PAC treated group. No gender difference in the withdrawal 
threshold was observed in PAC-treated rats (Fig. 2). 
An intraperitoneal injection of 2 mg/kg ketamine increased 
the mechanical threshold only in males (Fig. 3). However, no 
significant difference was observed between males and females. 
An intraperitoneal injection of 5 mg/kg ketamine increased 
the mechanical threshold in both genders. An intraperitoneal 
injection of 2 mg/kg or 5 mg/kg morphine increased the 
mechanical threshold in both genders dose dependently (Fig. 4). 
The combined use of 2 mg/kg morphine and 2 mg/kg ketamine 
Fig. 1. Changes in body weight after paclitaxel injection in rats. 
Paclitaxel (2 mg/kg) was injected intraperitoneally on 4 alternate 
days (days 1, 3, 5, and 7) in rats. The saline group received an equal 
volume (1 ml/kg) of saline. No significant difference in body weight 
was observed between the saline and PAC group. PAC: paclitaxel.
Fig. 2. The time course of mechanical withdrawal threshold after 
a paclitaxel injection. Paclitaxel (2 mg/kg) was injected intra-
peritoneally on 4 alternate days (days 1, 3, 5, and 7; cumulated doses 
of 8 mg/kg, P1, P2, P3, and P4) in rats. The saline group received an 
equal volume (1 ml/kg) of saline. After the third injection, paclitaxel 
significantly decreased mechanical thresholds compared with those 
in the saline group. No statistically significant gender difference 
was observed for paclitaxel-induced mechanical allodynia. PAC: 
paclitaxel, *P < 0.05 compared to saline group.69 www.ekja.org
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increased the mechanical threshold in both genders of rats (Fig. 5). 
Maximal possible effects (MPE) were calculated as: MPE 
= 100 × (threshold post injection - threshold at baseline)/
(15 - threshold at baseline). Morphine had dose-dependent 
analgesic effects in both genders. In contrast, ketamine showed 
a dose-dependent analgesic effect only in males. However, no 
significant difference was observed between males and females. 
The morphine and ketamine combination showed a statistically 
significant enhancement of the analgesic effect only in females, 
compared with individual injections of 2 mg/kg ketamine or 2 
mg/kg morphine (Table 1). 
Discussion 
In this PAC-induced neuropathic pain model, the mechanical 
threshold decreased on the day of the third PAC injection and 
was maintained until the end of the experiment. No gender 
difference was observed for the withdrawal threshold in PAC-
treated rats The PINP mechanism has not been revealed, and 
there are no validated drugs for prevention and treatment. 
Several experimental animal models of chemotherapy-related 
neurotoxicity have been developed to reveal the mechanism. 
The present study was conducted using the PAC model of 
Polomano et al. [2]. Some authors have suggested that chemo-
therapy-induced painful neuropathy is accompanied by 
ultrastructural changes in unmyelinated sensory neurons, 
including cytoskeletal disorganization and microtubule 
disorientation. One study indicated that the pain is associated 
with dysfunction in Aβ, Aδ, and C caliber primary afferent fibers 
[9]. Massive axonal degeneration occurs in post-traumatic 
painful peripheral neuropathy models, whereas animals with 
PINP have no axonal degeneration at the level of the peripheral 
Fig. 3. Analgesic effect of 2 mg/kg and 5 mg/kg ketamine in the rat paclitaxel-induced neuropathic pain model. (A) Ketamine (2 mg/kg) 
increased mechanical threshold only in males. No significant difference was observed between males and females. (B) Ketamine (5 mg/kg) 
increased mechanical threshold in both genders of rats without a difference. K2: 2 mg/kg ketamine, K5: 5 mg/kg ketamine, *P < 0.05 compared 
to baseline.
Fig. 4. Analgesic effect of 2 mg/kg (A) and 5 mg/kg (B) morphine in the rat paclitaxel-induced neuropathic pain model. Morphine dose-
dependently increased the mechanical threshold in both genders without a difference. M2: 2 mg/kg morphine, M5: 5 mg/kg morphine, *P < 0.05 
compared to baseline.70 www.ekja.org
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nerve [10,11]. PAC-treated rats have pronounced mechanical 
allodynia, cold allodynia, and mechanical hyperalgesia, but 
little or no heat hyperalgesia [2]. The nerve trauma models, such 
as the chronic constrictive injury model, produce the same 
symptoms but also produce pronounced heat hyperalgesia. 
Different mechanisms suggest the possibility of different pain 
responses and pharmacological response profiles.
Women are more likely than men to report acute and chronic 
pain [12] and use pain relieving medication significantly more 
often, even when pain frequency and severity is equaled 
between the genders [13]. Biological, cultural, psychological, 
and social factors are all hypothesized to contribute to these 
disparities in pain responses, reporting, and management 
[7]. In animals, most studies of gender differences in pain 
have examined acute nociception. In the partial nerve injury 
model, female rats are more susceptible to develop spread 
mechanical hypersensitivity, particularly after a facial nerve 
injury, compared with male rats. However, hypersensitivity of 
the hind paws after a sciatic nerve injury does not significantly 
differ between female and male rats [14], suggesting that gender 
differences in the neuropathic pain in rats depend on the site of 
injury and the type of test. 
In this study, an intraperitoneal injection of 2 mg/kg or 5 
mg/kg of morphine increased the mechanical threshold in both 
genders dose dependently. Opioid analgesic drugs are widely 
used for chronic pain, and morphine produces greater analgesia 
in males compared to that in female rats [15]. Three opioid 
receptors, μ, κ, and δ, are significantly implicated in modulating 
pain [16]. The μ receptor is the most clinically relevant receptor, 
as morphine and most other opioid agonists act preferentially 
at that site; thus, studies have focused most attention on this 
opioid receptor. In animal studies, the intensity of noxious 
stimulation used during pain testing influences the observed 
gender effect. Female predominance of μ-opioid analgesia is 
most notable at low to moderate intensities in thermal studies 
[17]. However, no significant difference in the anti-allodynic 
effect of morphine between male and female rats was observed 
in this study. 
Cata et al. [18] reported that PINP in rats is accompanied 
by changes in sensory processing by spinal cord neurons as 
evidenced by increased spontaneous activity, which is pro-
longed after discharges due to natural mechanical and thermal 
stimuli and increased windup to cutaneous electrical stimuli. 
Similar changes are observed in rats with vincristine-induced 
painful neuropathy [10], chronic constriction neuropathy, and 
partial nerve injury neuropathy [19], as well as in several models 
of central sensitization. Increased spontaneous activity in dorsal 
horn neurons has been hypothesized to result from increased 
discharge in peripheral neuromas or pathophysiological dorsal 
root ganglia neurons due to denervation supersensitivity, 
disinhibition, synaptic reorganization, post-synaptic 
activation of N-methyl-D-aspartate (NMDA) receptors, and 
cyclooxygenase type-2 induction [20]. An NMDA antagonist 
would be helpful to diminish after-discharge in the wide 
dynamic range neurons. In general, low dose ketamine does 
not produce an analgesic effect [21]. A maximally tolerated 
dose of MK-801 results in incomplete reversal of mechanical 
allodynia in PINP [22]. However, low dose ketamine (2 mg/kg) 
showed an analgesic effect in male rats in the present study. In 
females, 5 mg/kg ketamine resulted in a notable increase in the 
withdrawal threshold compared to that of 2 mg/kg ketamine, 
suggesting that NMDA activation may be related to gender and 
the mechanism of neuropathic pain. 
It has been established that the glutamate system interacts 
Fig. 5. Analgesic effect of combined 2 mg/kg morphine and 2 mg/
kg ketamine in the rat paclitaxel-induced neuropathic pain model. 
Combined use of 2 mg/kg morphine and 2 mg/kg ketamine increased 
the mechanical threshold without a gender difference. MK2: intra-
peritoneal injection of 2 mg/kg morphine and 2 mg/kg ketamine, *P < 
0.05 compared to baseline.
Table 1. Maximal Possible Effects of Ketamine, Morphine, or 
Combined Use of Ketamine and Morphine on Paclitaxel-Induced 
Neuropathic Pain in Rats 
Treatment Male Female
Ketamine 2 mg/kg i.p.
Ketamine 5 mg/kg i.p.
Morphine 2 mg/kg i.p.
Morphine 5 mg/kg i.p.
Ketamine 2 mg/kg +
  Morphine 2 mg/kg i.p
19.9 ± 23.4
46.6 ± 40.7
27.9 ± 30.3
85.8 ± 27.3
28.4 ± 37.4
7.1 ± 6.5
23.4 ± 21.1
21.6 ± 22.7
73.2 ± 34.7
56.1 ± 43.1*,†
No statistically significant difference was observed between males 
and females. A dose dependent increase in maximal possible effects 
occurred after the morphine injection in both genders. Ketamine (2 
mg/kg) enhanced the analgesic effect of morphine only in females. 
MPE (%); Maximal possible effect = 100 × (threshold of post injection 
- threshold of baseline) / (15 - threshold of baseline), K2: 2 mg/kg 
ketamine, K5: 5 mg/kg ketamine, M2: 2 mg/kg morphine, M5: 5 mg/
kg morphine, MK2: 2 mg/kg morphine and 2 mg/kg ketamine at the 
same time, *P < 0.05 compared to a 2 mg/kg injection of ketamine, 
†P < 0.05 compared to a 2 mg/kg injection of morphine.71 www.ekja.org
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with the opioid system. Opioids affect NMDA receptors, and 
NMDA receptors are involved in the development of opioid 
tolerance [23]. NMDA antagonists may potentiate opioid 
analgesia while preventing or slowing the development of 
opioid tolerance and dependence [24]. However, reports of 
NMDA antagonist modulation on the acute analgesic effects 
of opioid agonists vary from enhancement, to no effect, to 
attenuation [25-27]. In this study, 2 mg/kg ketamine enhanced 
the antinociceptive effect of 2 mg/kg morphine only in 
females. Some controversies exist as to the gender differences 
in the modulation of NMDA antagonists. Dextromethorphan 
enhances morphine analgesia in males but attenuates it in 
female rats [28]. In an acute pain model, there is enhancement 
of morphine antinociception by NMDA antagonist in both 
genders, but no effect is observed in females in a chronic 
pain model [29]. However, ketamine (3 mg/kg) produces a 
threefold increase in morphine (3 mg/kg) analgesia in female 
rats, whereas increase in morphine analgesia is negligible 
in male rats [21], which corresponds with the present study. 
These gender differences in the NMDA-opioid interaction 
are influenced by differences in neuroendocrine physiology, 
neurotransmitter density, and the physiological response 
to steroids [15,21]. The hippocampus of male rats contains 
significantly more AMPA, kainate, and NMDA receptors than 
those of female rats. Female rats in diestrus have significantly 
higher AMPA receptor densities than female rats in estrus [30]. 
These conflicting data show that morphine potentiation by 
NMDA antagonists follows a complex mechanism that may 
depend on the antinociceptive assay used, the pain model, and 
other factors such as type of antagonist, dose, and gender. 
The effect of chemotherapy on body weight varies based 
on the type of agent and administered dose. A volume of data 
indicates that chemotherapy-treated rats fail to gain weight 
during the treatment period [10,11]. However, no significant 
change was observed between the normal saline group and the 
PAC-injected group in the current study. Rats treated with PAC 
(2 mg/kg, days 1, 3, 5, 7) gained weight normally. The PAC dose 
was selected in a range that would induce neuropathic pain 
without other complications.
The present study did not include any information about 
the effect of the estrous cycle or gonadal hormones. Therefore, 
more studies are required to understand the exact mechanism 
and other factors. Further research to obtain more information 
about gender differences of other therapeutic drugs may aid in 
the development of better treatment for PINP. 
In summary, no difference in the incidence or severity of 
PINP was observed between male and female rats. No signi-
ficant difference was observed in the analgesic effects of mor-
phine or ketamine on the PINP. Low dose ketamine (2 mg/
kg i.p.) alone was not effective for increasing the withdrawal 
threshold in females. However, a notable enhancement of the 
analgesic effect was shown when administered in combination 
with morphine in females. The results suggest that ketamine 
may play a significant role in the treatment of PINP when 
combined with opioids, particularly in females. 
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